UA96768C2 - Лікарський засіб від lct-отруєнь - Google Patents

Лікарський засіб від lct-отруєнь

Info

Publication number
UA96768C2
UA96768C2 UAA200901716A UAA200901716A UA96768C2 UA 96768 C2 UA96768 C2 UA 96768C2 UA A200901716 A UAA200901716 A UA A200901716A UA A200901716 A UAA200901716 A UA A200901716A UA 96768 C2 UA96768 C2 UA 96768C2
Authority
UA
Ukraine
Prior art keywords
poisoning
medicament
lct
lcts
large clostridial
Prior art date
Application number
UAA200901716A
Other languages
English (en)
Russian (ru)
Inventor
Айхельштрайбер Крістоф фон
Джесіка Райнеке
Штефан Тенцер
Хансйорг Шильд
Мая Рупнік
Original Assignee
Йоганес Гутенберг-Універсітет Майнц
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006036373A external-priority patent/DE102006036373A1/de
Priority claimed from DE102007004938A external-priority patent/DE102007004938A1/de
Application filed by Йоганес Гутенберг-Універсітет Майнц filed Critical Йоганес Гутенберг-Універсітет Майнц
Publication of UA96768C2 publication Critical patent/UA96768C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Лікарський засіб для попередження або ослаблення наслідків отруєння великими клостридіальними цитотоксинами (LCT), зокрема токсинами А та В (TcdA, TcdB) Clostridium difficile, який відрізняється тим, що як активну речовину він містить щонайменше один ефектор, а саме інгібітор або активатор автокаталітичної активності протеази цитотоксинів LCT.
UAA200901716A 2006-08-02 2007-05-26 Лікарський засіб від lct-отруєнь UA96768C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006036373A DE102006036373A1 (de) 2006-08-02 2006-08-02 Arzneimittel gegen LCT-Vergiftungen
DE102007004938A DE102007004938A1 (de) 2007-01-26 2007-01-26 Arzneimittel gegen LCT-Vergiftungen
PCT/DE2007/000957 WO2008014733A1 (de) 2006-08-02 2007-05-26 Arzneimittel gegen lct-vergiftungen

Publications (1)

Publication Number Publication Date
UA96768C2 true UA96768C2 (uk) 2011-12-12

Family

ID=38521891

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200901716A UA96768C2 (uk) 2006-08-02 2007-05-26 Лікарський засіб від lct-отруєнь

Country Status (9)

Country Link
US (3) US20090311258A1 (uk)
EP (1) EP2054044B1 (uk)
JP (2) JP5345532B2 (uk)
AU (1) AU2007280861B2 (uk)
CA (1) CA2659684A1 (uk)
ES (1) ES2507553T3 (uk)
RU (1) RU2465893C2 (uk)
UA (1) UA96768C2 (uk)
WO (1) WO2008014733A1 (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
MX2011005758A (es) * 2008-12-03 2011-06-28 Boehringer Ingelheim Vetmed Procedimiento para la produccion de vacunas.
BR112014007405B1 (pt) * 2011-09-29 2021-07-13 Eth Zurich Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica
EP2788022B1 (en) 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
SG10201610123UA (en) * 2012-03-02 2017-01-27 Regeneron Pharma Human antibodies to clostridium difficile toxins
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
JPH0429621Y2 (uk) * 1988-01-23 1992-07-17
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
FR2770844A1 (fr) * 1997-11-10 1999-05-14 Inst Nat Sante Rech Med Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6415234B1 (en) * 1998-08-03 2002-07-02 Glyco Design Inc. Designing inhibitors for glycosyltransferases
AU5122700A (en) * 1999-04-09 2000-11-14 Johns Hopkins University, The Channel forming toxins as antiviral agents
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AU784755B2 (en) * 1999-12-15 2006-06-08 Merck Sharp & Dohme Corp. Daptomycin Analogs as antibacterial agents
AU2003231157C1 (en) * 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
US20040208944A1 (en) * 2002-06-26 2004-10-21 Armand Malnoe Compositions and methods against inflammatory processes
BR0312985A (pt) * 2002-07-26 2005-06-21 Inst Medical W & E Hall Métodos para extrair ou induzir, em um mamìfero, uma resposta imune dirigida a um parasita, para tratar de modo terapêutico ou profilático um mamìfero para infecção por parasitas, para o tratamento e/ou a profilaxia de uma condição doentia de mamìfero, uso de uma composição,composição, composição de vacina, composição farmacêutica, anticorpo para inibir, parar ou retardar o inìcio ou progressão de uma condição doentia de mamìfero, uso de um anticorpo, métodos para detectar, em uma amostra bológica, uma molécula imunointerativa dirigida a um microorganismo e para detectar, monitorar ou de outra forma avaliar uma resposta imune dirigida a um microorganismo em um indivìduo, kit modular, método para analisar, projetar e/ou modificar um agente capaz de interagir com um sìtio de ligação de molécula imunointerativa anti-gpi glicano, e, uso do agente
JP4557514B2 (ja) * 2003-07-15 2010-10-06 住友電工焼結合金株式会社 内接歯車式ポンプ及びそのポンプのインナーロータ
DK1766093T3 (da) * 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
ES2479515T3 (es) * 2004-07-26 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Composición terapéutica con una neurotoxina botulínica
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
WO2006046112A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
WO2007060618A2 (en) * 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Macrolides derivatives as antibacterial agents
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
US20110218176A1 (en) * 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8110551B2 (en) * 2008-01-22 2012-02-07 The Trustees Of The University Of Pennsylvania Cytolethal distending toxin and use thereof
MX2011005758A (es) * 2008-12-03 2011-06-28 Boehringer Ingelheim Vetmed Procedimiento para la produccion de vacunas.
US20100137563A1 (en) * 2008-12-03 2010-06-03 Northwestern University Cysteine Protease Autoprocessing of Fusion Proteins
WO2011034622A2 (en) * 2009-09-21 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
MX2012003398A (es) * 2009-09-25 2012-04-10 Alcon Res Ltd Agonistas npr-b novedosos.
WO2012138963A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof
SI2699587T1 (sl) * 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
WO2012166991A1 (en) * 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
BR112014007405B1 (pt) * 2011-09-29 2021-07-13 Eth Zurich Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica

Also Published As

Publication number Publication date
JP2009545536A (ja) 2009-12-24
JP5777594B2 (ja) 2015-09-09
US20150344531A1 (en) 2015-12-03
AU2007280861A1 (en) 2008-02-07
EP2054044A1 (de) 2009-05-06
WO2008014733A9 (de) 2009-01-29
US20090311258A1 (en) 2009-12-17
RU2465893C2 (ru) 2012-11-10
EP2054044B1 (de) 2014-07-23
JP2013067630A (ja) 2013-04-18
CA2659684A1 (en) 2008-02-07
US9066961B2 (en) 2015-06-30
AU2007280861B2 (en) 2013-02-07
US20130280286A1 (en) 2013-10-24
JP5345532B2 (ja) 2013-11-20
RU2009107138A (ru) 2010-09-10
WO2008014733A1 (de) 2008-02-07
ES2507553T3 (es) 2014-10-15

Similar Documents

Publication Publication Date Title
UA96768C2 (uk) Лікарський засіб від lct-отруєнь
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
MX2009009552A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
WO2022035911A3 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
MX2009007637A (es) Composiciones y metodos para control de pestes.
TW200716119A (en) A solid pharmaceutical dosage formulation
HN2008001652A (es) Compuesto y composiciones como modulares de la senda de hedgehog
AU2003267624A1 (en) Wound treatment device
WO2007098352A3 (en) Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
RS54863B1 (sr) Upotreba sredstva za suzbijanje vlažne truleži i postupak suzbijanja iste
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
DK1704859T3 (da) Kontrol af androgen receptor-afhængig genenkspression ved inhibering af amin-oxidase-aktiviteten af lysin-specifik demetylase (LSD1)
MX2007003196A (es) Agente y alimento para evitar/mejorar el trastorno digestivo funcional.
WO2008097546A3 (en) Compounds that inhibit cholinesterase
WO2009002823A3 (en) Tableted compositions containing atazanavir
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
WO2009002829A3 (en) Tableted compositions containing atazanavir
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2009051223A1 (ja) 白内障処置のための医薬組成物
NO20065459L (no) Fremgangsmate for a behandle mikrobielle plantesykdommer
WO2009038095A1 (ja) セサミン類とビタミンｂ１類とを配合した組成物
TWI256292B (en) Reduction inhibitory agent for active oxygen eliminating activity
WO2009002821A3 (en) Tableted compositions containing atazanavir
MY152388A (en) Composition and method for controlling plant diseases